Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Rubio

Showing results (301-310 of 320) with videos related to

Pageof 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 11, 2025
Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - Results from the prospective AXSANA registry trialRosa Di Micco, Steffi Hartmann, Maggie Banys-Paluchowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III TrialSuzette Delaloge, Martine Piccart, Emiel Rutgers, et al.
Eclinicalmedicine|August 2, 2023
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensusOrit Kaidar-Person, André Pfob, Oreste Davide Gentilini, et al.
The Lancet. Oncology|January 2, 2021
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolboxPeter Dubsky, Katja Pinker, Fatima Cardoso, et al.
The Lancet. Oncology|March 15, 2021
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Laura J van 't Veer, Coralie Poncet, et al.
The New England Journal of Medicine|August 25, 2016
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerFatima Cardoso, Laura J van't Veer, Jan Bogaerts, et al.
NPJ Breast Cancer|July 27, 2021
Evaluation of multiple transcriptomic gene risk signatures in male breast cancerJane Bayani, Coralie Poncet, Cheryl Crozier, et al.
The Lancet. Oncology|November 27, 2025
The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensusAndré Pfob, Katja Pinker, Ines Vaz-Luis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramF Cardoso, J M S Bartlett, L Slaets, et al.
EMBO Molecular Medicine|November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Pageof 32

Showing results (301-310 of 320) with videos related to

Sort By:
Pageof 32
European Journal of Cancer (Oxford, England : 1990)|July 11, 2025
Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - Results from the prospective AXSANA registry trialRosa Di Micco, Steffi Hartmann, Maggie Banys-Paluchowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III TrialSuzette Delaloge, Martine Piccart, Emiel Rutgers, et al.
Eclinicalmedicine|August 2, 2023
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensusOrit Kaidar-Person, André Pfob, Oreste Davide Gentilini, et al.
The Lancet. Oncology|January 2, 2021
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolboxPeter Dubsky, Katja Pinker, Fatima Cardoso, et al.
The Lancet. Oncology|March 15, 2021
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Laura J van 't Veer, Coralie Poncet, et al.
The New England Journal of Medicine|August 25, 2016
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerFatima Cardoso, Laura J van't Veer, Jan Bogaerts, et al.
NPJ Breast Cancer|July 27, 2021
Evaluation of multiple transcriptomic gene risk signatures in male breast cancerJane Bayani, Coralie Poncet, Cheryl Crozier, et al.
The Lancet. Oncology|November 27, 2025
The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensusAndré Pfob, Katja Pinker, Ines Vaz-Luis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramF Cardoso, J M S Bartlett, L Slaets, et al.
EMBO Molecular Medicine|November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Pageof 32